ABSTRACT

Artificial intelligence (AI) is rapidly transforming the landscape of drug development. The traditional medicinal product life cycle, from target identification to post-marketing surveillance, is undergoing a transformation driven by Artificial Intelligence (AI). This review explores the current advancements in integrating AI across various stages of drug development. We analyse how AI is revolutionizing target discovery, accelerating drug design, optimizing clinical trials, and enhancing post-marketing safety monitoring. The review highlights the potential benefits of AI, including increased efficiency, improved accuracy, and personalized medicine approaches. We also acknowledge the challenges associated with AI integration, such as data quality concerns, regulatory considerations, and the need for human-AI collaboration. Finally, the review discusses future directions for AI in the pharmaceutical industry, emphasizing the potential for a more data-driven and efficient drug development process. This review provides a comprehensive picture of the current state-of-the-art and the exciting possibilities that AI holds for the future of drug development, life-saving medicines to market. Keywords: Artificial Intelligence, Lifecycle of Medicinal Product, Product life cycle management, Future Prospects
Publication date: 01/08/2025

https://ijbpas.com/pdf/2025/August/MS_IJBPAS_2025_9292.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.8.9292